Abstract
Objective: This study aimed to determine whether there is a difference in pain scores and opioid consumption after elective surgery in patients maintained on methadone or buprenorphine for opioid use disorder (OUD). Additionally, we investigated the impact of continuing or discontinuing methadone or buprenorphine on post-operative pain outcomes.
Design: A single-center retrospective cohort study.
Setting: Tertiary care medical center.
Patients and participants: Adults aged 18 years or older with OUD maintained on buprenorphine or methadone who underwent elective surgery between January 1, 2017, and January 1, 2021.
Interventions: Patients were identified through electronic medical records, and demographic and clinical data were collected.
Main outcome measures: The primary outcome was opioid consumption at 24 hours post-operatively, measured in milligram morphine equivalents. The secondary outcome was opioid consumption and pain scores up to 72 hours postoperatively, assessed using a numeric rating scale.
Results: This study included 366 patients (64 percent on buprenorphine and 36 percent on methadone). Opioid utilization significantly increased when buprenorphine was not administered post-operatively. Both groups exhibited comparable total opioid consumption during the post-operative period. In the buprenorphine cohort, pain scores differed significantly based on the receipt of medications for OUD post-operatively.
Conclusions: This study reinforces existing evidence supporting the continuation of medications for opioid use disorder, specifically buprenorphine and methadone, during the perioperative period. Dissemination of guideline recommendations is essential to ensure optimal post-operative pain management for this patient population.
Publisher
Weston Medical Publishing
Reference31 articles.
1. Alderks CE: Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003-2015 (update). The CBHSQ Report: August 22, 2017. Substance Abuse and Mental Health Services Administration (US), 2017.
2. Schuler MS, Saloner B, Gordon AJ, et al.: National trends in buprenorphine treatment for opioid use disorder from 2007 to 2018. Subst Abus. 2023; 44: 154-163.
3. Biondi BE, Vander Wyk B, Schlossberg EF, et al.: Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Addict Sci Clin Pract. 2022; 17(1): 15.
4. Hser YI, Evans E, Huang D, et al.: Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016; 111(4): 695-705.
5. Mattick RP, Breen C, Kimber J, et al.: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014; 2014(2): Cd002207.